Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Stopped Funding Sponsor decision due to review of efficacy data from other trials involving investigational product.

Conditions

• Acute Myeloid Leukemia

Interventions

• DRUG: Venetoclax
• DRUG: Azacitidine
• BIOLOGICAL: Donor Lymphocyte Infusion

Sponsor

Antonio M Jimenez Jimenez

Collaborators

• [object Object]